WP
EPRX

Woodline Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Woodline Partners’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94M Buy
746,864
+306,313
+70% +$2.11M 0.02% 693
2026
Q1 		$3.19M Buy
+440,551
New +$3.55M 0.01% 739

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners's EPRX Position: Q2 2026 in Review

Woodline Partners increased its Eupraxia Pharmaceuticals (EPRX) stake by 70% in Q2 2026, buying an estimated $2.11M and bringing the position to 746,864 shares worth $4.94M. The position accounts for 0.02% of the portfolio, ranked #693.

Woodline Partners first reported a position in EPRX in Q1 2026 and has held it in 2 quarters since. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Woodline Partners held 746,864 shares of Eupraxia Pharmaceuticals worth $4.94M as of Q2 2026.
  • Woodline Partners bought 306,313 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $2.11M.
  • Eupraxia Pharmaceuticals made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #693 holding.
  • Woodline Partners first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.